Cargando…

Ex Vivo Characterization of a Novel Iodine-123-Labelled Aminomethylchroman as a Potential Agonist Ligand for SPECT Imaging of Dopamine D(2/3) Receptors

For imaging of dopamine D(2/3) receptors, agonist tracers are favoured over antagonists because they are more sensitive to detection of dopamine release and because they may selectively label the high-affinity receptor state. We have developed novel D(2/3) receptor selective agonists that can be rad...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Wieringen, Jan-Peter, de Bruin, Kora, Janssen, Henk M., Fransen, P. Michel, Janssen, Anton G. M., van Doremalen, Peter A., Michel, Martin C., Elsinga, Philip H., Booij, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291083/ https://www.ncbi.nlm.nih.gov/pubmed/25610643 http://dx.doi.org/10.1155/2014/507012

Ejemplares similares

Synthesis and evaluation in rats of homologous series of [(18)F]-labeled dopamine D(2/3) receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers
por: Shalgunov, Vladimir, et al.
Publicado: (2015)

Agonist signalling properties of radiotracers used for imaging of dopamine D(2/3) receptors
por: van Wieringen, Jan-Peter, et al.
Publicado: (2014)

Clinical evaluation of [(123)I]FP-CIT SPECT scans on the novel brain-dedicated InSPira HD SPECT system: a head-to-head comparison
por: Adriaanse, Sofie M., et al.
Publicado: (2018)

No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [(123)I]FP-CIT (DaTSCAN) and SPECT
por: Thomsen, Gerda, et al.
Publicado: (2013)

Imaging of serotonin transporters with [(123)I]FP-CIT SPECT in the human hypothalamus
por: Borgers, Anke J, et al.
Publicado: (2013)

Evaluation of Iodine-123 and Iodine-131 SPECT activity quantification: a Monte Carlo study
por: Morphis, Michaella, et al.
Publicado: (2021)

A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [(123)I]I-FP-CIT SPECT in routine practice
por: Chahid, Youssef, et al.
Publicado: (2023)

The SPECT tracer [(123)I]ADAM binds selectively to serotonin transporters: a double-blind, placebo-controlled study in healthy young men
por: van de Giessen, Elsmarieke, et al.
Publicado: (2010)

AMPT-induced monoamine depletion in humans: evaluation of two alternative [(123)I]IBZM SPECT procedures
por: Boot, Erik, et al.
Publicado: (2008)

Lower (123)I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson's disease compared with dementia with Lewy bodies
por: Joling, Merijn, et al.
Publicado: (2018)

((123)I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study
por: Siepel, Françoise J, et al.
Publicado: (2013)

Iodine-123-metaiodobenzylguanidine cardiac SPECT imaging in the qualification of heart failure patients for ICD implantation
por: Teresińska, Anna
Publicado: (2018)

Comparison of [(18)F]-FDOPA PET and [(123)I]-FP-CIT SPECT acquired in clinical practice for assessing nigrostriatal degeneration in patients with a clinically uncertain parkinsonian syndrome
por: Wallert, Elon, et al.
Publicado: (2022)

Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An (123)I-FP-CIT SPECT study
por: Joling, Merijn, et al.
Publicado: (2019)

Bipolar Disorder and Parkinson's Disease: A (123)I-Ioflupane Dopamine Transporter SPECT Study
por: Erro, Roberto, et al.
Publicado: (2021)

Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients
por: Zaaijer, Eline R., et al.
Publicado: (2015)

Synthesis and In Vitro Evaluation of Novel Nortropane Derivatives as Potential Radiotracers for Muscarinic M(2) Receptors
por: Knol, Remco J. J., et al.
Publicado: (2011)

Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer's disease pathology: An (123)I-FP-CIT SPECT study
por: van der Zande, J.J., et al.
Publicado: (2019)

Dopamine transporter imaging with [(18)F]FE-PE2I PET and [(123)I]FP-CIT SPECT—a clinical comparison
por: Jakobson Mo, Susanna, et al.
Publicado: (2018)

The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [(123)I]FP-CIT SPECT imaging
por: Dickson, John C., et al.
Publicado: (2017)

The role of (123)I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies
por: Antonini, Angelo
Publicado: (2007)

Striatal dopamine D(2/3) receptors in medication-naïve schizophrenia: an [(123)I] IBZM SPECT study
por: Chen, Kao Chin, et al.
Publicado: (2022)

Iodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging
por: Chrastina, Adrian, et al.
Publicado: (2010)

[(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies
por: van der Zande, J. J., et al.
Publicado: (2016)

Dose-dependent effects of the selective serotonin reuptake inhibitor citalopram: A combined SPECT and phMRI study
por: Schrantee, Anouk, et al.
Publicado: (2019)

The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review
por: Suwijn, Sven R, et al.
Publicado: (2015)

Autonomic failure in Parkinson’s disease is associated with striatal dopamine deficiencies
por: van Deursen, Dagmar N., et al.
Publicado: (2020)

Individual parkinsonian motor signs and striatal dopamine transporter deficiency: a study with [I-123]FP-CIT SPECT
por: Mäkinen, Elina, et al.
Publicado: (2019)

FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder
por: Meles, Sanne K., et al.
Publicado: (2017)

Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with ((123)I) ioflupane in diagnosis of parkinsonian syndromes
por: Bajaj, Nin, et al.
Publicado: (2013)

Reliability of visual assessment by non-expert nuclear medicine physicians and appropriateness of indications of [(123)I]FP-CIT SPECT imaging by neurologists in patients with early drug-naive Parkinson’s disease
por: Suwijn, Sven R., et al.
Publicado: (2019)

The Effects of Ecstasy (MDMA) on Brain Serotonin Transporters Are Dependent on Age-of-First Exposure in Recreational Users and Animals
por: Klomp, Anne, et al.
Publicado: (2012)

Validation of a SIMIND Monte Carlo modelled gamma camera for Iodine-123 and Iodine-131 imaging
por: Morphis, Michaella, et al.
Publicado: (2021)

CT-Based Attenuation Correction in I-123-Ioflupane SPECT
por: Lange, Catharina, et al.
Publicado: (2014)

The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes
por: Uyama, Naoto, et al.
Publicado: (2017)

Hunting for the high‐affinity state of G‐protein‐coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging
por: Shalgunov, Vladimir, et al.
Publicado: (2018)

Discriminating among degenerative parkinsonisms using advanced (123)I-ioflupane SPECT analyses
por: Badoud, Simon, et al.
Publicado: (2016)

Performance evaluation of a novel brain-dedicated SPECT system
por: Stam, M. K., et al.
Publicado: (2018)

Dopamine Transporter SPECT Imaging in Corticobasal Syndrome
por: Cilia, Roberto, et al.
Publicado: (2011)

Loss of thalamic serotonin transporters in early drug-naïve Parkinson’s disease patients is associated with tremor: an [(123)I]β-CIT SPECT study
por: Caretti, V., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_79vc71g8hvh5bhods00aakkkkn